<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>242308</rcn>
  <id>101100628</id>
  <acronym>NANOFLD</acronym>
  <teaser>Obesity is a catalyst for numerous conditions; the most notable is non-alcoholic fatty liver disease (NAFLD), for which currently no drug therapy has been approved by the FDA and EMA for its treatment. The endocannabinoid (eCB) system triggers the development of obesity and...</teaser>
  <objective>Obesity is a catalyst for numerous conditions; the most notable is non-alcoholic fatty liver disease (NAFLD), for which currently no drug therapy has been approved by the FDA and EMA for its treatment. The endocannabinoid (eCB) system triggers the development of obesity and its related comorbidities, specifically NAFLD. eCBs, via activating the cannabinoid-1 receptors (CB1Rs) in the liver, increase hepatic glucose production, insulin resistance, and de novo lipogenesis, and decrease fatty acid oxidation. Accordingly, globally-acting CB1R blockers improve these parameters both in rodents and humans. However, owing to their neuropsychiatric side effects, they were withdrawn from the market and are no longer available for clinical use. NANOFLD aims to revive their clinical development and testing by utilizing an innovative nanometric drug delivery system for the hepatic targeting of globally-acting CB1R blockers for treating NAFLD. In the framework of my ERC-StG grant, CaNanoBinoids, my team successfully encapsulated the first-in-class CB1R blocker, rimonabant, in nanoparticles (NPs), tested their stability, efficacy, and potency, and demonstrated their therapeutic potential in ameliorating NAFLD, insulin resistance, and dyslipidemia in mice. To further translate our findings into clinical practice, the present PoC application builds on and expands this avenue of research by achieving several necessary steps including biodistribution, hepatic cellular fate, and PK studies of our novel nanometric drug delivery system. Importantly, we have secured the IP, conducted a specific market assessment, targeted regulatory constraints, implemented a business development plan, consulted with professionals in the field, and developed contacts with industry. When this project is completed, we expect to have introduced a unique innovation to treat NAFLD and its metabolic abnormalities, further promoting the idea to clinically test CB1R blockers encapsulated in NPs against NAFLD.</objective>
  <title>Nano-Technology Enabled Repositioning of Cannabinoids for Treating NAFLD</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2022-11-01</startDate>
  <endDate>2024-04-30</endDate>
  <ecSignatureDate>2022-09-29</ecSignatureDate>
  <duration>18</duration>
  <status>CLOSED</status>
  <identifiers>
    <grantDoi>10.3030/101100628</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>true</euroSciVoc>
  </validation>
  <sourceUpdateDate>2022-10-02 22:32:16</sourceUpdateDate>
  <contentCreationDate>2022-10-06 17:59:25</contentCreationDate>
  <contentUpdateDate>2022-10-06 17:59:20</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:49:05</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>438750</rcn>
        <id>438750-nanoparticle-drug-delivery-system-for-fatty-liver-disease</id>
        <title>Nanoparticle drug delivery system for fatty liver disease</title>
        <contentUpdateDate>2023-03-21 11:16:02</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <organization netEcContribution="150000" totalCost="0" source="corda" order="1" ecContribution="150000" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1905975</rcn>
        <id>999975038</id>
        <vatNumber>IL500701610</vatNumber>
        <legalName>THE HEBREW UNIVERSITY OF JERUSALEM</legalName>
        <shortName>THE HEBREW UNIVERSITY OF JERUSALEM</shortName>
        <address>
          <street>EDMOND J SAFRA CAMPUS GIVAT RAM</street>
          <city>JERUSALEM</city>
          <postalCode>91904</postalCode>
          <country>IL</country>
          <postBox>000</postBox>
          <url>http://www.huji.ac.il</url>
          <geolocation>31.77293975,35.1979949541527</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706736</rcn>
        <id>HORIZON_ERC-2022-POC2</id>
        <code>ERC-2022-POC2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS2</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1237446</rcn>
        <id>101100628_BA0BFCA9041D0386867AA04688FDE605_IPRHORIZON</id>
        <title>PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS</title>
        <details>
          <iprAwarded></iprAwarded>
          <iprNumber>23050611</iprNumber>
          <iprDate>2023-06-14</iprDate>
          <iprPrefix>20</iprPrefix>
        </details>
        <sourceUpdateDate>2025-01-10 11:51:31</sourceUpdateDate>
        <contentUpdateDate>2025-01-10 11:51:31</contentUpdateDate>
        <relations>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages>en</availableLanguages>
              <rcn>1905975</rcn>
              <id>999975038</id>
              <vatNumber>IL500701610</vatNumber>
              <legalName>THE HEBREW UNIVERSITY OF JERUSALEM</legalName>
              <shortName>THE HEBREW UNIVERSITY OF JERUSALEM</shortName>
              <address>
                <street>EDMOND J SAFRA CAMPUS GIVAT RAM</street>
                <city>JERUSALEM</city>
                <postalCode>91904</postalCode>
                <country>IL</country>
                <postBox>000</postBox>
                <url>http://www.huji.ac.il</url>
                <geolocation>31.77293975,35.1979949541527</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
                    <code>/HES</code>
                    <title>Higher or Secondary Education Establishments</title>
                    <displayCode>/Higher or Secondary Education Establishments</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Israel</name>
                    <rcn>307661352</rcn>
                    <nutsCode>IL</nutsCode>
                    <euCode>IL</euCode>
                    <isoCode>IL</isoCode>
                  </region>
                  <region type="relatedRegion">
                    <name>Israel</name>
                    <rcn>307661352</rcn>
                    <nutsCode>IL</nutsCode>
                    <euCode>IL</euCode>
                    <isoCode>IL</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode>/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PATENT</code>
              <title>Patent</title>
              <displayCode>/Patent</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1127853</rcn>
        <id>101100628_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - NANOFLD (Nano-Technology Enabled Repositioning of Cannabinoids for Treating NAFLD)</title>
        <description>periodic</description>
        <teaser>The project centers around addressing a pressing health concern: Nonalcoholic fatty liver disease (NAFLD) and its progression into more severe conditions like non-alcoholic steatohepatitis (NASH), which can lead to liver fibrosis, cirrhosis, and even cancer. With the rise of...</teaser>
        <sourceUpdateDate>2024-07-05 06:13:19</sourceUpdateDate>
        <contentUpdateDate>2024-07-08 12:27:12</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101100/101100628_PS/ga-legend300.jpg</uri>
              <mimetype>image/jpeg</mimetype>
              <size>1375232</size>
            </webItem>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997/1615</code>
        <title>lipids</title>
        <displayCode>/natural sciences/biological sciences/biochemistry/biomolecules/lipids</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/30013</code>
        <title>hepatology</title>
        <displayCode>/medical and health sciences/clinical medicine/hepatology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/25/69/435</code>
        <title>nano-materials</title>
        <displayCode>/engineering and technology/nanotechnology/nano-materials</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/33/117/38005658</code>
        <title>obesity</title>
        <displayCode>/medical and health sciences/health sciences/nutrition/obesity</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode>/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>